Searchable abstracts of presentations at key conferences in endocrinology

ea0099p352 | Reproductive and Developmental Endocrinology | ECE2024

Early response with fezolinetant treatment of moderate-to-severe vasomotor symptoms associated with menopause in women considered unsuitable for hormone therapy: phase 3b daylight study

Linden Hirschberg Angelica , Bouchard Celine , Cano Antonio , Schaudig Katrin , Martins Karla , Miyazaki Kentaro , Wu Xi , Wang Xuegong

Introduction: There is a need for well tolerated and effective nonhormonal therapies for vasomotor symptoms (VMS) associated with menopause. Fezolinetant is a nonhormonal, selective neurokinin 3 receptor antagonist that is approved for the treatment of moderate-to-severe VMS associated with menopause.Objective: To assess how early a response to fezolinetant in frequency and severity of moderate-to-severe VMS was observed in the 24-week placebo-controlled...